You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Claims for Patent: 12,005,069

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 12,005,069

Title:	Bortezomib compositions
Abstract:	The present disclosure relates to ready-to-use liquid aqueous bortezomib compositions bortezomib and pharmaceutical excipients. Other aspects include methods of preparing such ready-to-use liquid aqueous bortezomib compositions, and methods of using such ready-to-use liquid bortezomib compositions in therapeutic applications.
Inventor(s):	Srikanth Sundaram, Daniel Charles Stewart
Assignee:	Maia Pharmaceuticals Inc
Application Number:	US18/456,759
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 12,005,069
Patent Claims:	1. A liquid, ready-to-use aqueous composition consisting of about 1 mg/mL bortezomib, about 10 mg/mL mannitol, about 20 mg/mL dimethyl sulfoxide, about 0.82 mg/mL sodium acetate, water and, optionally, hydrochloric acid, sodium hydroxide, or a combination thereof, wherein the pH of the ready-to-use composition is about 5 to about 6. 2. The composition of claim 1, wherein the composition has a pH of about 5.5 to about 6. 3. The composition of claim 1, wherein the composition is in a vial where the head space is filled with nitrogen. 4. A liquid, ready-to-use aqueous composition consisting of about 2.5 mg/mL bortezomib, about 25 mg/mL mannitol, about 22 mg/mL dimethyl sulfoxide, about 0.82 mg/mL sodium acetate, water and, optionally, hydrochloric acid, sodium hydroxide, or a combination thereof, wherein the pH of the ready-to-use composition is about 5 to about 6. 5. The composition of claim 4, wherein the composition has a pH of about 5.25 to about 5.75. 6. The composition of claim 4, the composition is in a vial where the head space is filled with nitrogen. 7. A liquid, ready-to-use aqueous composition consisting of bortezomib, mannitol, dimethyl sulfoxide, sodium acetate, water and, optionally, hydrochloric acid, sodium hydroxide, or a combination thereof, wherein (i) the pH of the ready-to-use composition is about 5 to about 6 and (ii) after storage at 2-8° C. for 12 months, at least 90% of the bortezomib remains in the composition.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.